Diabetic Retinopathy Market Share, Size, Trends, Industry Analysis Report, By Type (Proliferative DR, Non-proliferative DR); By Management (Intraocular Steroid Injection, Laser Surgery, Vitrectomy); By Region, And Segment Forecasts, 2023 - 2032

Diabetic Retinopathy Market Share, Size, Trends, Industry Analysis Report, By Type (Proliferative DR, Non-proliferative DR); By Management (Intraocular Steroid Injection, Laser Surgery, Vitrectomy); By Region, And Segment Forecasts, 2023 - 2032

The global diabetic retinopathy market size is expected to reach USD 15.23 billion by 2032, according to a new study by Polaris Market Research. The report “Diabetic Retinopathy Market Share, Size, Trends, Industry Analysis Report, By Type (Proliferative DR, Non-proliferative DR); By Management (Intraocular Steroid Injection, Laser Surgery, Vitrectomy); By Region, And Segment Forecasts, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The incidence of diabetes has been witnessing a significant surge, with a substantial impact on global health. According to the International Diabetes Federation, the number of individuals affected by diabetes was approximately 537 million in 2021. This figure is projected to increase to 643 million by 2030 and a staggering 783 million by 2045. Diabetes is recognized as one of the leading causes of blindness worldwide.

Blindness in individuals with diabetes is often attributed to the damage caused by leaking or ruptured blood vessels in the retina. The severity of vision loss can vary, ranging from permanent impairment to temporary disruptions depending on the stage of the disease. Research indicates that the number of cases of diabetic retinopathy, a specific form of vision impairment associated with diabetes, was estimated to be around 103.12 million in 2020. It is anticipated that the number of cases will escalate to approximately 160.5 million by 2045.

The aging population presents unique challenges in terms of healthcare needs, including a higher prevalence of chronic diseases like diabetes. With advancements in medical care and improved life expectancy, the number of individuals aged 65 years and over is projected to escalate substantially. For instance, the ""Aging in the United States"" report by the Population Reference Bureau indicates that the population of individuals aged 65 years and above in the U.S. is estimated to grow from approximately 46 million in 2016 to over 98 million by the year 2060.

This demographic shift underscores the importance of addressing health issues associated with aging, including diabetic retinopathy. Healthcare providers and manufacturers in the market must be prepared to meet the growing demands of this expanding population and provide effective solutions to manage diabetic retinopathy and preserve vision in older adults.

The COVID-19 pandemic had a substantial impact on healthcare systems worldwide, including the diagnosis and treatment of diabetic retinopathy. Due to the constraints and restrictions imposed during the pandemic, early detection and treatment guidelines for diabetic retinopathy were significantly affected. Intravitreal injections, which are a common treatment modality for diabetic retinopathy, experienced a significant decrease in usage globally during the pandemic compared to 2019. Reduction percentages varied but ranged from approximately 30% to over 100%.

Diabetic Retinopathy Market Report Highlights

Non-proliferative diabetic retinopathy segment accounted for highest global market share in 2022, due to rise in number of cases of diabetes

Anti-VEGF segment accounted largest share, due its high efficacy and better treatment algorithm

Asia Pacific region grown at the fastest rate, owing huge un-tapped population and better patient awareness

The global key market players include Bayer, Allergan, Novartis, Oxurion, Sirnaomics, Genentech, Alimera Sciences, Ampio Pharmaceuticals, BCN Peptides, and Kowa Company.

Polaris Market Research has segmented the diabetic retinopathy market report based on type, management, and region:

Diabetic Retinopathy, Type Outlook (Revenue - USD Billion, 2019 - 2032)

Proliferative Diabetic Retinopathy

Non-proliferative diabetic retinopathy

Diabetic Retinopathy, Management Outlook (Revenue - USD Billion, 2019 - 2032)

Anti-VEGF

Intraocular Steroid Injection

Laser Surgery

Vitrectomy

Diabetic Retinopathy, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa